Kalinox (Nitrous Oxide, Oxygen)

Nitrous oxide produces its effects by blocking NMDA receptors, modulating opioid pathways and enhancing GABA activity in the central nervous system. This combination results in analgesia, anxiolysis, and a modest level of sedation while the oxygen component helps maintain adequate tissue oxygenation.

The dose of Kalinox is individualized. A qualified prescriber determines the appropriate concentration, flow rate and duration based on the patient’s clinical condition, the procedure being performed and the desired level of analgesia.

Data on nitrous oxide use in pregnancy are limited, and the gas is generally avoided unless the benefit clearly outweighs potential risks. Breastfeeding mothers should consult a healthcare professional before using Kalinox, as safety has not been fully established.

To order Kalinox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Kalinox combines nitrous oxide with oxygen, offering analgesia while reducing the risk of hypoxia compared with nitrous oxide alone. Compared with volatile anesthetics, it has a faster onset and recovery, making it suitable for brief procedures and settings where rapid titration is needed.

Kalinox cylinders should be stored at ambient temperature in a well‑ventilated area, protected from heat, direct sunlight and physical damage. They must be secured upright, and handling should follow the manufacturer’s safety guidelines to prevent accidental release or exposure.

Kalinox is delivered via a calibrated inhalation system, typically using a face mask or nasal cannula. The gas flow is adjusted to achieve the desired concentration, and the patient inhales the mixture under continuous monitoring of oxygen saturation and vital signs.

The most serious risks include hypoxia, respiratory depression, loss of consciousness and severe hypotension. These events are rare when the gas is administered with appropriate oxygen supplementation and proper monitoring, but they require immediate medical intervention if they occur.

Kalinox should be avoided in patients with untreated pneumothorax, severe chronic obstructive pulmonary disease, middle‑ear barotrauma, or known hypersensitivity to nitrous oxide. It is also contraindicated in individuals who cannot be adequately monitored or who have conditions that predispose them to hypoxia.